Title : Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.

Pub. Date : 2015 Feb 20

PMID : 25605014






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Overall, our studies demonstrate that patients screened for Top2a and Ezh2 expression would exhibit significant response to a combinational treatment involving low dose etoposide combined with Ezh2 inhibition. Etoposide DNA topoisomerase II alpha Homo sapiens